ライフサイエンスコーパス: cardiovascular disease

1 singly prevalent modifiable risk factors for cardiovascular disease.

2 impaired glucose metabolism, contributes to cardiovascular disease.

3 nonalcoholic fatty liver disease (NAFLD), or cardiovascular disease.

4 pirin prescribed for secondary prevention of cardiovascular disease.

5 uilt environment features that are linked to cardiovascular disease.

6 ss index 35+/-5 kg/m(2)]) without coexisting cardiovascular disease.

7 th a doubling of the risk of atherosclerotic cardiovascular disease.

8 ess, has emerged as a biomarker for arterial cardiovascular disease.

9 ose tissue is associated with higher risk of cardiovascular disease.

10 tion in patients with coronary artery and/or cardiovascular disease.

11 function, and metabolic syndrome, leading to cardiovascular disease.

12 elationship between PR interval duration and cardiovascular disease.

13 and inflammation strongly drive the risk of cardiovascular disease.

14 evated lipoprotein(a) levels and established cardiovascular disease.

15 d inflammation is the primary determinant of cardiovascular disease.

16 ears) is expected to lead to higher rates of cardiovascular disease.

17 irin has been proposed to reduce the risk of cardiovascular disease.

18 in resistance, type 2 diabetes mellitus, and cardiovascular disease.

19 )) are associated with an increased risk for cardiovascular disease.

20 -day PCSK9 therapeutics for the treatment of cardiovascular disease.

21 ve investigations of CKD as a risk factor of cardiovascular disease.

22 d it initially to annotate drugs relevant to cardiovascular disease.

23 might be useful for ameliorating the risk of cardiovascular disease.

24 ribute to common conditions such as gout and cardiovascular disease.

25 in modern society and increases the risk of cardiovascular disease.

26 pient death were malignancy, infections, and cardiovascular disease.

27 of diet-related chronic disease, especially cardiovascular disease.

28 ncreases all-cause mortality and the risk of cardiovascular disease.

29 linical condition that accelerates renal and cardiovascular disease.

30 hould not be used in high-risk patients with cardiovascular disease.

31 e myocardial trabeculae on susceptibility to cardiovascular disease.

32 s in the comorbidity of major depression and cardiovascular disease.

33 ntal cause of poor health and disparities in cardiovascular disease.

34 a major causal factor in the development of cardiovascular disease.

35 rticularly HXP and LXP) impact upon risk for cardiovascular disease.

36 , and clinical trials targeting PCSK9 reduce cardiovascular disease.

37 co-specific therapeutics in the treatment of cardiovascular disease.

38 ility to a second heat stroke, infection and cardiovascular disease.

39 ariant, P387 TSP4, have been associated with cardiovascular disease.

40 tate the development of new therapeutics for cardiovascular diseases.

41 ecognized for their functions in controlling cardiovascular diseases.

42 modynamics and increase the severity of many cardiovascular diseases.

43 ticles that are relevant to the treatment of cardiovascular diseases.

44 tant in vascular dysfunction associated with cardiovascular diseases.

45 ascular system and the mechanisms underlying cardiovascular diseases.

46 tween obesity, type 2 diabetes mellitus, and cardiovascular diseases.

47 isk factor for obesity, type 2 diabetes, and cardiovascular diseases.

48 the 101 patients, hypertension (38, 37.6%), cardiovascular disease (21,20.8%), diabetes (18,17.8%),

49 disease were at increased risk of death from cardiovascular disease (3.5 vs 3.4 per 1000 person-years

50 diabetes, 15 on adverse birth outcomes, 8 on cardiovascular disease, 3 each on obesity and rheumatoid

51 nts, with hypertension (59%), obesity (47%), cardiovascular disease (38%), and diabetes (33%) being t

52 e analyzed, of which 8,765 (26%) were due to cardiovascular disease; 5,777 (17%) were due to neoplasm

53 ective, the volume tax would prevent 850 000 cardiovascular disease (95% CI, 836 000-864 000) and 269

54 Outcomes included cardiovascular disease (a composite of myocardial infarc

55 -Macrin PET imaging could stage inflammatory cardiovascular disease activity, assist disease manageme

56 NDER database to examined temporal trends in cardiovascular disease age-adjusted mortality rates over

57 ning health implications of cannabis include cardiovascular diseases, although they may be mediated b

58 s 0.70 (95% CI, 0.57 to 0.85) for death from cardiovascular disease and 0.77 (95% CI, 0.61 to 0.96) f

59 nesis of several chronic diseases, including cardiovascular disease and Alzheimer disease, as well as

60 ed and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis.

61 udy to VITAL, a randomized clinical trial of cardiovascular disease and cancer prevention among 25 87

62 to risks of various chronic diseases such as cardiovascular disease and cancer.

63 9) and BMP10 is of significant importance in cardiovascular disease and cancer.

64 mmendations for transforming surveillance of cardiovascular disease and cardiovascular health in the

65 ll as a firmly established increased risk of cardiovascular disease and chronic kidney disease in tho

66 s that have the greatest effects on averting cardiovascular disease and death globally, with addition

67 er frequency of medication intake related to cardiovascular disease and diabetes in patients with per

68 conduct and analysis of clinical trials for cardiovascular disease and heart failure.

69 critical to ultimately reduce the burden of cardiovascular disease and improve cardiovascular health

70 t valve disease is a common manifestation of cardiovascular disease and is a significant cause of car

71 ce or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, u

72 rial involving patients with atherosclerotic cardiovascular disease and low-density lipoprotein chole

73 o guide counseling of affected families with cardiovascular disease and may guide primary interventio

74 population-attributable fractions (PAFs) for cardiovascular disease and mortality associated with a c

75 ar exercise is associated with lower risk of cardiovascular disease and mortality, mechanisms of exer

76 nsion is a common modifiable risk factor for cardiovascular disease and mortality.

77 mean 24-hour BP associated with high risk of cardiovascular disease and progression of kidney disease

78 Thus, screening for cardiovascular disease and risk stratification for cardi

79 rial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) leve

80 c structure and function are associated with cardiovascular diseases and a wide range of other types

81 s a cluster of interrelated risk factors for cardiovascular diseases and atherosclerosis.

82 s human conditions, including autoimmune and cardiovascular diseases and cancer.

83 s) found in ultrafine PM have been linked to cardiovascular diseases and carcinogenic and mutagenic e

84 lications of native and bioengineered EVs to cardiovascular diseases and examine the opportunities an

85 l for the early assessment and prevention of cardiovascular diseases and respiratory disorders.

86 s a depot for Na(+) accumulation in multiple cardiovascular diseases and risk factors.

87 diseases with an immune component, including cardiovascular diseases and susceptibility to infections

88 the pathogenesis and development of various cardiovascular diseases and, therefore, represents a pot

89 with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience m

90 tudy (HPFS; 1986-2016) who were free of T2D, cardiovascular disease, and cancer at baseline.

91 valence of chronic kidney disease, diabetes, cardiovascular disease, and chronic respiratory disease.

92 hronic diseases such as Alzheimer's disease, cardiovascular disease, and diabetes.

93 are influenced by NAFLD are type 2 diabetes, cardiovascular disease, and impaired neurocognitive func

94 Elderly patients, those with established cardiovascular disease, and mechanically ventilated pati

95 solid organ malignancies, diabetes mellitus, cardiovascular disease, and obstructive sleep apnea, res

96 h a higher risk of obesity, type 2 diabetes, cardiovascular disease, and premature mortality, whereas

97 e the risks of obesity, type 2 diabetes, and cardiovascular disease, and recent studies have also ide

98 onverting enzyme 2 (ACE2) is dysregulated in cardiovascular disease, and this enzyme is used by sever

99 lood pressure, a significant risk factor for cardiovascular disease, and, thus, limits its applicatio

100 Older adults with cardiovascular disease are frequently admitted to cardia

101 IV) are at increased risk of atherosclerotic cardiovascular disease (ASCVD) and are prone to statin-r

102 ations of Lp(a) and FHx with atherosclerotic cardiovascular disease (ASCVD) and CHD among asymptomati

103 ated with increased risk for atherosclerotic cardiovascular disease (ASCVD) events.

104 College of Cardiology (ACC) atherosclerosis cardiovascular disease (ASCVD) risk score.

105 sociated with a low risk for atherosclerotic cardiovascular disease (ASCVD).

106 erythematosus predispose to atherosclerotic cardiovascular disease (ASCVD).

107 pective longitudinal study of adults free of cardiovascular disease at baseline.

108 ounting evidence implicating inflammation in cardiovascular diseases, attempts at clinical translatio

109 Stress is linked to negative outcomes in cardiovascular diseases but exactly why is unclear.

110 iplatelet therapy reduces ischemic events in cardiovascular disease, but it increases bleeding risk.

111 ospitalization were predominantly related to cardiovascular disease, but other causes contributed, pa

112 of cardiovascular risk factors and incident cardiovascular disease, but risks differed by quality of

113 appear to be an independent risk factor for cardiovascular disease, but the pathological basis for t

114 evolving recognition that efforts to prevent cardiovascular disease can have synergistic benefit in p

115 n various pathological conditions, including cardiovascular disease, cancer, diabetes and chronic neu

116 holesterolemia is characterized by premature cardiovascular disease caused by markedly elevated level

117 th, leaving individuals at elevated risk for cardiovascular disease, certain types of cancers, and ne

118 utcomes and develop a chronic kidney disease-cardiovascular disease (CKD-CVD) health outcomes model,

119 on, smoking, and family history of premature cardiovascular disease contributed to progression, with

120 In patients with pre-LT cardiovascular disease, creatinine levels 12 months afte

121 e that >2 million Americans with established cardiovascular diseases currently use or have used marij

122 Cardiovascular disease (CVD) affects individuals of all

123 and calcification, which is associated with cardiovascular disease (CVD) and all-cause mortality.

124 ion are major players in the pathogenesis of cardiovascular disease (CVD) and Alzheimer's disease (AD

125 Cardiovascular disease (CVD) and associated comorbiditie

126 Cardiovascular disease (CVD) and cancer are leading caus

127 Secondary outcomes were cardiovascular disease (CVD) and cancer mortality.

128 F), myocardial infarction (MI), stroke (ST), cardiovascular disease (CVD) and chronic kidney disease

129 ic blood pressures provide information about cardiovascular disease (CVD) but are only extremes of th

130 Inflammation plays an important role in cardiovascular disease (CVD) development.

131 us (HIV) may affect the risk of death due to cardiovascular disease (CVD) differently in men versus w

132 be most consistent in its ability to add to cardiovascular disease (CVD) event prediction.

133 n a cohort of pregnant women with underlying cardiovascular disease (CVD) followed by a cardio-obstet

134 Cardiovascular disease (CVD) has become an increasingly

135 Statins may help prevent cardiovascular disease (CVD) in people with HIV (PWH) wi

136 Cardiovascular disease (CVD) is the leading cause of dea

137 Cardiovascular disease (CVD) is the leading cause of dea

138 Cardiovascular disease (CVD) is the major cause of morbi

139 rmaceutical drugs targeting dyslipidemia and cardiovascular disease (CVD) may increase the risk of fa

140 Whereas cardiovascular disease (CVD) metrics define risk in indi

141 ciate with composite and individual incident cardiovascular disease (CVD) outcomes including myocardi

142 tenuate the benefits of physical activity on cardiovascular disease (CVD) risk and overall mortality.

143 etween the degree of risk factor control and cardiovascular disease (CVD) risk in type 2 diabetes and

144 ucing saturated fat (SFA) intake to decrease cardiovascular disease (CVD) risk, but there is limited

145 with reduced kidney function have increased cardiovascular disease (CVD) risk.

146 y antagonism in CHIP carriers would decrease cardiovascular disease (CVD) risk.

147 omen and minorities are under-represented in cardiovascular disease (CVD) specialties.

148 n particular,is an important risk factor for cardiovascular disease (CVD) through increased levels of

149 pants (mean age 62.5 +/- 11.7 years) without cardiovascular disease (CVD) were recruited from the Car

150 ompartments) with mortality from all causes, cardiovascular disease (CVD), and cancer.

151 Periodontitis is positively linked to cardiovascular disease (CVD), diabetes, cancer, and incr

152 Cardiovascular disease (CVD), including coronary artery

153 mption and smoking, 2 major risk factors for cardiovascular disease (CVD), often occur together.

154 e intersection between diabetes mellitus and cardiovascular disease (CVD), pharmacologic agents used

155 d T2DM) increase the risk of atherosclerotic cardiovascular disease (CVD), resulting in acute cardiov

156 ich the RVLM could contribute chronically to cardiovascular disease (CVD).

157 rthritis (RA) are at high risk of developing cardiovascular disease (CVD).

158 iabetes increase the risk of atherosclerotic cardiovascular disease (CVD).

159 Atherosclerosis is the major cause of cardiovascular disease (CVD).

160 with and without history of atherosclerotic cardiovascular disease (CVD).

161 estyle is associated with increased risk for cardiovascular disease (CVD).

162 portant pathological consequences, including cardiovascular disease (CVD).

163 ulations often as the first manifestation of cardiovascular disease (CVD).

164 fining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD).

165 respiratory infections are risk factors for cardiovascular disease (CVD).

166 arbohydrate intake may determine the risk of cardiovascular disease (CVD).

167 dyslipidemia treatment in those at risk for cardiovascular disease (CVD).

168 s (T2D) is associated with increased risk of cardiovascular disease (CVD).

169 which are associated with increased risk of cardiovascular disease (CVD).

170 hose of infectious etiology, as well as with cardiovascular diseases (CVD).

171 Cardiovascular diseases (CVDs) cause significant mortali

172 Aortic stiffness is closely linked with cardiovascular diseases (CVDs), but recent studies sugge

173 Cardiovascular diseases (CVDs), principally ischemic hea

174 s (HRs) of first all-cause and type-specific cardiovascular diseases (CVDs).

175 pendently associated with subsequent risk of cardiovascular diseases (CVDs).

176 As cardiovascular disease decreases in many countries, mort

177 ion studies without baseline atherosclerotic cardiovascular disease: DHS (Dallas Heart Study; n=2535)

178 rtality and morbidity, with contributions to cardiovascular disease, diabetes mellitus, fatty liver d

179 2019 (COVID-19) is strongly associated with cardiovascular disease, diabetes, and hypertension.

180 Older age, tobacco use, underlying cardiovascular disease, diabetes, and renal disease were

181 These variations mean that the profile of cardiovascular disease differs between low-income and hi

182 Cardiovascular disease disparities are shaped by differe

183 Efforts to eliminate cardiovascular disease disparities have recently emphasi

184 has also emerged as a therapeutic target for cardiovascular disease due to its ability to remodel car

185 Worryingly, the prevalence of acquired cardiovascular disease during pregnancy is rising as old

186 equires a team approach to the management of cardiovascular disease during pregnancy.

187 stic events to decrease the risk for certain cardiovascular diseases (e.g., coronary heart disease, h

188 e of clinical events (AIDS, non-AIDS cancer, cardiovascular disease, end-stage liver and renal diseas

189 modifying the "risk factors" established by cardiovascular disease epidemiology would prevent heart

190 ents with comorbidities and prior history of cardiovascular disease events at baseline and within the

191 The individual-level risk of atherosclerotic cardiovascular disease events in primary prevention popu

192 A 12% relative risk reduction in cardiovascular disease events was used for the 5-year nu

193 Major incident cardiovascular disease events were associated with ESKD,

194 for secondary prevention of atherosclerotic cardiovascular disease events.

195 ssification (RC) at 12 months and subsequent cardiovascular disease events.

196 es in symptom classification with subsequent cardiovascular disease events.

197 e that diets with protective effects against cardiovascular disease exert an anti-atherothrombotic ef

198 hose with two conditions in addition to T2D, cardiovascular diseases featured in 18 of the top 20 com

199 icipants age 45 to 84 years without clinical cardiovascular disease from the prospective MESA (Multi-

200 and 1300 black postmenopausal women without cardiovascular disease from the Women's Health Initiativ

201 particulate matter <=2.5 mum in diameter) in cardiovascular disease has emerged.

202 Advanced phenotyping of cardiovascular diseases has evolved with the application

203 known sex differences in PTSD prevalence and cardiovascular disease, here we tested whether the effec

204 2.48; 95% CI, 1.21-5.05), history of pre-LT cardiovascular disease (HR, 2.19; 95% CI, 1.2-3.98), and

205 on scientific statement on air pollution and cardiovascular disease in 2010, unequivocal evidence of

206 cal factors determine a higher likelihood of cardiovascular disease in a distinctive context of concu

207 the prevention of premature atherosclerotic cardiovascular disease in all at-risk patients and famil

208 ts in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus.

209 namics) is an independent risk predictor for cardiovascular disease in patients, but its genetic basi

210 functional effects that provide insight into cardiovascular disease in people living with HIV.

211 lays the foundation for precise diagnosis of cardiovascular disease in real time.

212 6 years was associated with a lower risk of cardiovascular disease in the offspring when they were y

213 lopment of novel antiplatelet drugs to fight cardiovascular diseases in humans.

214 DAD) study has reported an increased risk of cardiovascular diseases in people with human immunodefic

215 edge of the genetic basis of atherosclerotic cardiovascular disease-in particular, coronary artery di

216 iac parameters reflecting cardiac injury and cardiovascular disease, including heart contractility, m

217 m cancer are now more common than those from cardiovascular disease, indicating a transition in the p

218 As the mechanism accounting for cardiovascular disease is prevalently due to the atherot

219 High awareness that cardiovascular disease is the leading cause of death (LC

220 Among adults aged 35-70 years, cardiovascular disease is the major cause of mortality g

221 ding metabolic state for type 2 diabetes and cardiovascular disease is widely recognised.

222 s, and plays a crucial role in hypertension, cardiovascular disease, kidney disease, and fluid homeos

223 ional age offspring are at increased risk of cardiovascular disease later in life.

224 Cardiovascular diseases lead to 31.5% of deaths globally

225 gh-density lipoprotein (HDL) cholesterol and cardiovascular disease, leading to the hypothesis that t

226 was to estimate the prevalence of monogenic cardiovascular diseases (MCVDs) and potentially missed d

227 Rates of first hospital admission and cardiovascular disease medication use were lowest in LIC

228 cular outcomes in patients with a history of cardiovascular disease (moderate strength) or diabetes m

229 and HR: 1.0, 0.76, and 0.52 in cohort 2) and cardiovascular disease mortality (HR: 1.0, 0.55, and 0.4

230 sity is among the leading causes of elevated cardiovascular disease mortality and morbidity.

231 er multiple risk factors for atherosclerotic cardiovascular disease (n=10 186) or known atherosclerot

232 disease (n=10 186) or known atherosclerotic cardiovascular disease (n=6974).

233 Cardiovascular disease occurred more often in LICs (7.1

234 tatus (SES) and measures of small vessel and cardiovascular disease on observed race differences.

235 -10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascu

236 tios for all-cause mortality and deaths from cardiovascular disease or cancer over 10 years according

237 participants aged 45 to 84 without baseline cardiovascular disease or HF who had data on GlycA and i

238 nd low grip strength had stronger effects on cardiovascular disease or mortality than in HICs.

239 nt's previous history of AF, atherosclerotic cardiovascular disease, or HF.

240 We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients wit

241 traditionally associated with improvement in cardiovascular disease outcomes in patients with ischemi

242 ESA participants (n = 4,184 subjects free of cardiovascular disease), PA was measured by waist-secure

243 Ischemic cardiovascular diseases, particularly acute myocardial i

244 ssociation studies, the genetic landscape of cardiovascular diseases, particularly for the nonfamilia

245 alidated microsimulation model, CVD-PREDICT (Cardiovascular Disease Policy Model for Risk, Events, De

246 We used the Cardiovascular Disease Policy Model-Argentina (CVD Polic

247 morbidity of major psychiatric disorders and cardiovascular disease, potentially through dysregulatio

248 D in immune-driven conditions with increased cardiovascular disease prevalence.

249 ke, mortality, prescription medications, and cardiovascular disease procedures.

250 s implement a clinical assessment to curtail cardiovascular disease progression but are limited to th

251 high-risk population of older patients with cardiovascular disease, randomization to ramipril had no

252 ascular aspects of the aging process and its cardiovascular disease related manifestations.

253 mendations for prevention of atherosclerotic cardiovascular disease rely principally on estimated 10-

254 Cardiovascular diseases remain the leading cause of dise

255 causal role of alcohol consumption for other cardiovascular diseases requires further research.

256 HIV-related cardiovascular disease research is predominantly from Eu

257 diovascular risk categories (Agatston score; cardiovascular disease risk categories: 0, 1-10, 11-100,

258 cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial)

259 Elevated cardiovascular disease risk factor burden is a recognize

260 ators of preparedness of countries to manage cardiovascular disease risk factors (CVDRFs) are regular

261 Models were adjusted for sociodemographics, cardiovascular disease risk factors, and inflammatory bi

262 in obese adolescents and are associated with cardiovascular disease risk factors, HsCRP and Ox-LDL.

263 ve function score, adjusting for traditional cardiovascular disease risk factors.

264 ent in 1993 or 1999, reported information on cardiovascular disease risk factors.

265 ultivariable adjustment for demographics and cardiovascular disease risk factors.

266 uideline for managing dyslipidemia to reduce cardiovascular disease risk in adults.

267 rticles deficient in SERPINA1 could increase cardiovascular disease risk in subjects with diabetes me

268 ary artery calcium score and atherosclerotic cardiovascular disease risk score for MACE prediction.

269 assessment and management of atherosclerotic cardiovascular disease risk.

270 pment of type 2 diabetes (T2D) and increases cardiovascular disease risk.

271 contradicted previous conclusions on EPA for cardiovascular disease risk.

272 ging phenotypes can be used to better define cardiovascular disease risks as well as heart-brain heal

273 e care is commensurate with high age-related cardiovascular disease risks but where the associated ge

274 with a variety of health endpoints including cardiovascular disease, sleep disturbance, depression, a

275 in patients with different manifestations of cardiovascular disease, such as coronary artery disease,

276 Disruption of BMP signaling can trigger cardiovascular diseases, such as arteriovenous malformat

277 For complex cardiovascular diseases, such as heart failure, systems

278 the importance of cardiovascular health and cardiovascular disease surveillance systems for the acqu

279 Finally, cardiovascular disease susceptibility genes identified u

280 Genes involved in both longevity and cardiovascular diseases, taken as a paradigmatic example

281 n approach can be expanded to apply to other cardiovascular disease targets and emerging therapeutic

282 ve sleep apnea-hypopnea syndrome (OSAHS) and cardiovascular diseases, the effect of mandibular advanc

283 t similar pathways are active in humans with cardiovascular disease, these studies suggest that the c

284 inical conditions, such as kidney, liver, or cardiovascular disease, those who have opportunistic dis

285 es mellitus without clinical atherosclerotic cardiovascular disease to guide the use of preventive ph

286 BAT has been implicated to be protective in cardiovascular disease, to this point there are no studi

287 and degenerative diseases including cancer, cardiovascular diseases, type 2 diabetes mellitus, obesi

288 The incidence of major cardiovascular disease was associated with increased ris

289 Risk of diabetes mellitus, depression, and cardiovascular disease was significantly higher for THIN

290 In 2015-2018, cardiovascular disease was the most common cause of deat

291 the multivariate model, age, female sex, and cardiovascular disease were associated with an increased

292 03 [14.7%] women, 2046 [33.4%] with previous cardiovascular disease) were enrolled and randomly alloc

293 engineering is a promising approach to treat cardiovascular diseases, which are a major socio-economi

294 n, we randomly assigned participants without cardiovascular disease who had an elevated INTERHEART Ri

295 than did placebo among participants without cardiovascular disease who were at intermediate cardiova

296 center integrated healthcare system, free of cardiovascular disease, with available data on HF risk f

297 ABO blood group is associated with cardiovascular disease, with significantly lower risk in

298 ars of age with a history of atherosclerotic cardiovascular disease without safety concerns around us

299 Heart failure (HF) is a major cardiovascular disease worldwide, and the early detectio

300 ated subjects with type 2 diabetes (T2D) and cardiovascular disease, yet exhibit considerable inter-i